MedTrace Logo

Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib

NCT05473468 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-11-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

Famitinib

a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-26
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05473468 on ClinicalTrials.gov